ImmunoEdge

Cover Block

Attribute	Value
Name	ImmunoEdge
Tagline	Unlocking immune targets from minimal tumor samples for precision immunotherapy in various diseases.
Headquarters	Heidelberg, Germany
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Unknown
Funding Label	Unknown

Links

• Website: https://www.immunoedge.de
• LinkedIn: https://www.linkedin.com/company/immunoedge

What an Investor Needs First

ImmunoEdge is a Heidelberg-based biotech startup developing a high-sensitivity, low-loss technology to uncover clinically relevant tumor peptides from minimally invasive biopsies, a critical bottleneck for next-generation immunotherapies [BioRN, Q1 2026]. Founded in 2023, the company's public emergence came with its admission to the BioRN life-science cluster in early 2026, where it was described as supporting actionable target discovery and longitudinal monitoring throughout treatment [BioRN, Q1 2026]. Its core technical claim addresses a known industry problem: current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from the small biopsy samples that are the clinical reality for many patients [ImmunoEdge, retrieved 2026]. By aiming to extract deeper molecular insights from ultra-low-input material, the platform seeks to enable higher-confidence discovery of immune-visible targets, particularly those missed by genome-based prediction methods [ImmunoEdge, retrieved 2026].

The founding team and any external funding have not been publicly disclosed. The business model is presumed B2B, targeting biopharma and biotech companies developing cancer immunotherapies. Over the next 12-18 months, key signals to watch will be the disclosure of technical validation data, the naming of founders and initial investors, and the announcement of any research collaborations or pilot programs with established oncology players.

Data Accuracy: YELLOW -- Core product claims are sourced from the company's own materials and a cluster announcement; team and funding details are absent from public records.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Biotech / Life Sciences
Technology Type	Deeptech
Geography	Western Europe (Heidelberg, Germany)
Growth Profile	Venture Scale

Inside the Company

ImmunoEdge first appears in the public record in the first quarter of 2026, listed as a new member of the BioRN life-science cluster in Germany's Rhine-Neckar region [BioRN, Q1 2026]. The company describes itself as a Heidelberg-based biotech startup founded in 2023. The company's primary public presence is a LinkedIn page, which lists its industry as biotechnology [LinkedIn].

A discrepancy exists regarding its headquarters. While the BioRN membership announcement explicitly lists Heidelberg, Germany, the company's LinkedIn page lists Redwood City, California [BioRN, Q1 2026] [LinkedIn]. No information on legal entity structure is available from public filings.

The company's sole verifiable milestone is its admission to the BioRN cluster in Q1 2026 [BioRN, Q1 2026].

Data Accuracy: YELLOW -- Key company descriptors are sourced from a single cluster announcement and an unverified LinkedIn page, with a material conflict on headquarters location.

Under the Hood

ImmunoEdge is building a platform for immunopeptidomics, the study of peptides presented on the cell surface by immune molecules. The company's core claim is a method that recovers more clinically relevant tumor peptides from far smaller tissue samples than standard workflows allow [BioRN, Q1 2026]. Current affinity-based workflows can lose up to 99% of potential immunopeptides when working with the low-input tumor material typical of minimally invasive biopsies [ImmunoEdge, retrieved 2026]. The technology is designed to reduce this loss and bias, aiming to make longitudinal monitoring of a patient's tumor antigen landscape throughout treatment a practical reality [ImmunoEdge, retrieved 2026].

A key differentiator is sensitivity at low input. The company states its platform can uncover immune-visible tumor peptides from ultra-low-input biopsies that standard methods miss, unlocking insights for rare and low-input cell populations [ImmunoEdge, retrieved 2026]. The intended output is a higher-confidence set of potential immunotherapy targets, or neoepitopes, moving beyond genome-based predictions [ImmunoEdge, retrieved 2026]. The product surface is described as supporting actionable target discovery and longitudinal monitoring for next-generation immunotherapies like personalized cancer vaccines and T-cell therapies [BioRN, Q1 2026].

Public details on the specific biochemical or engineering techniques are absent. No technical specifications, performance benchmarks against established methods, or details of a commercial product format have been disclosed. The technology is presented as being "designed for clinical reality" [ImmunoEdge, retrieved 2026].

Data Accuracy: YELLOW -- Core claims are sourced from the company's own materials and a cluster announcement; no independent technical validation or customer case studies are available.

Market Research

The market for technologies that can translate small, real-world tumor biopsies into actionable immunotherapy targets is defined by a fundamental mismatch between clinical sample availability and the technical requirements of existing discovery platforms.

The global personalized cancer vaccine market was valued at $2.3 billion in 2024 and is projected to reach $7.8 billion by 2030, growing at a compound annual rate of 22.5% [Precedence Research, 2024].

Demand is driven by the shift towards less invasive, serial biopsies for treatment monitoring [ImmunoEdge, retrieved 2026]. Simultaneously, the clinical validation of mRNA-based personalized cancer vaccines has intensified the search for reliable, tumor-specific peptide targets [BioRN, Q1 2026]. A third driver is the expansion of cell therapies into solid tumors, which requires the identification of safe and effective targets from often heterogeneous and scarce tissue samples.

Metric	Value
Personalized Cancer Vaccines 2024	$2.3B
Personalized Cancer Vaccines 2030	$7.8B

Data Accuracy: YELLOW -- Market sizing is drawn from a single third-party report for an analogous, downstream market. Specific TAM/SAM for the immunopeptidomics tools segment is not confirmed.

Competition and Substitutes

ImmunoEdge enters a competitive field defined by large-scale platform companies and specialized biotech players.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
ImmunoEdge	High-sensitivity, low-loss tumor peptide discovery from minimal biopsies for immunotherapy target ID and monitoring.	Pre-Seed (estimated). No public funding.	Focus on ultra-low-input clinical samples and longitudinal monitoring from small biopsies.	[BioRN, Q1 2026]
Immatics	Clinical-stage biotech developing TCR-based immunotherapies and XPRESIDENT® target discovery platform.	Public (Nasdaq: IMTX). Over $1B market cap.	Integrated pipeline from proprietary target discovery to clinical-stage T-cell therapies.	[Immatics, 2024]
NantWorks	Holding company with subsidiaries in AI-driven healthcare and immunotherapy.	Private. Multi-billion dollar portfolio.	Broad ecosystem integrating diagnostics, data analytics, and therapeutic development.	[NantWorks, 2024]
Illumina	Global leader in DNA sequencing and array-based technologies for genomic analysis.	Public (Nasdaq: ILMN). ~$20B market cap.	Dominant market share in sequencing hardware and consumables for genomic research.	[Illumina, 2024]
Waters	Analytical instrument manufacturer for liquid chromatography, mass spectrometry, and bioanalytical workflows.	Public (NYSE: WAT). ~$20B market cap.	Provider of core instrumentation for proteomics and metabolomics research labs.	[Waters, 2024]

Data Accuracy: YELLOW -- Competitive positioning is sourced from company descriptions and public filings; ImmunoEdge's specific technical differentiator is from a single cluster announcement.

Opportunity

The potential prize for ImmunoEdge is the creation of a foundational data layer for the next wave of personalized cancer immunotherapies. ImmunoEdge's stated aim is to unlock these targets from the small, serial biopsies that are a clinical reality in oncology [BioRN, Q1 2026].

Scenario	What happens	Catalyst	Why it's plausible
Platform Partner	ImmunoEdge's technology is licensed or embedded into the R&D workflows of top-20 oncology-focused biopharma companies.	A published, peer-reviewed validation study demonstrating superior peptide recovery from low-input clinical samples versus standard methods.	The industry's reliance on external innovation for target discovery is established.
Diagnostic Enabler	The company transitions from a discovery service to providing a regulated assay or kit for longitudinal monitoring of immunotherapy patients.	Securing a CE mark or FDA breakthrough device designation for a monitoring application.	The push for real-time, minimally invasive biomarkers to track treatment response is a major trend.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated aims and well-documented industry needs, but specific catalysts and comparables are extrapolated from the broader market context.

Sources

1. [BioRN, Q1 2026] Introducing our New Members - Q1 2026 | https://biorn.org/introducing-our-new-members-q1-2026/
2. [ImmunoEdge, retrieved 2026] ImmunoEdge | https://www.immunoedge.de
3. [LinkedIn] ImmunoEdge LinkedIn Page | https://www.linkedin.com/company/immunoedge
4. [Precedence Research, 2024] Personalized Cancer Vaccine Market | https://www.precedenceresearch.com/personalized-cancer-vaccine-market
5. [Immatics, 2024] Immatics Corporate Website | https://www.immatics.com
6. [NantWorks, 2024] NantWorks Corporate Website | https://www.nantworks.com
7. [Illumina, 2024] Illumina Corporate Website | https://www.illumina.com
8. [Waters, 2024] Waters Corporate Website | https://www.waters.com
9. [public financials, 2025] Immatics Market Capitalization | https://finance.yahoo.com/quote/IMTX/